Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Samuel Isaly and OrbiMed Advisors Reduced Anthera Pharmaceuticals $ANTH

Samuel Isaly’s OrbiMed Advisors manages around $5 Billion in healthcare related equities and venture capital. Eaton Vance Worldwide Health Sciences Fund managed to beat the S&P 500 index by more than 5 percentage points per year since Isaly took over in 1989. Isaly has economics degrees from Princeton and the London School of Economics.

This week OrbiMed started selling nearly 130 thousand shares of Anthera Pharmaceuticals (ANTH). They received around $7.23 per share on the average. OrbiMed still has more than 3.3 Million shares of Anthera. ANTH was trading below $4 at the beginning of February. The 75+% return might have induced some profit taking. Anthera’s large shareholder Vantagepoint Venture Associates sold nearly 700 thousand shares earlier this month. Jacob Gottlieb’s Visium Asset Management also had 1.6 Million shares of ANTH in its portfolio at the end of December.

According to Yahoo Finance Anthera Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on developing and commercializing therapeutics to treat diseases associated with inflammation, including cardiovascular and autoimmune diseases. Its primary product candidates include varespladib methyl (A-002), which has completed its Phase 2 clinical studies for the treatment of acute coronary syndrome; varespladib sodium (A-001) that is in a Phase 2 clinical study for the prevention of acute chest syndrome associated with sickle cell disease; and A-623, which has completed Phase 1 clinical studies for the treatment of B-cell mediated autoimmune diseases. The company has license agreements with Eli Lilly and Company, and Shionogi & Co., Ltd. to develop and commercialize secretory phospholipase A2 or sPLA2 inhibitors for the treatment of cardiovascular disease and other diseases; and Amgen Inc., to develop and commercialize A-623. Anthera Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Hayward, California.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!